Clinical trial NCT05219916: Selection of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent HIV Proviruses
Official title: Selection of Farnesoid X Receptor (FXR) Ligands as Latency Reversal Agents (LRA) of Latent HIV Proviruses in Circulating CD4+ T Lymphocytes Isolated From Patients With Undetectable HIV Viremia Under cART (Combined Antiretroviral Treatments)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Human Immunodeficiency Virus I Infection
Keywords: HIV
LRA
FXR
Reactivation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2022-02-02
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Descriptive physiopathological study
Primary purpose: BASIC_SCIENCE

Brief summary: The FXReservoir#1 study (NCT03618862) showed that certain FXR ligands reactivate latent viruses in the reservoir circulating in all HIV+ patients tested. These molecules appear as latency reversal agents (LRA) of silent viruses of the HIV reservoir. They can be part of the strategy to eradicate this reservoir, responsible for recurrences of the infection when combined anti-retroviral treatments are stopped.

Two effective leads have been identified on in vitro tests and on ex vivo reactivation using FXReservoir#1. These molecules come from a chemical library of FXR ligands developed by the Inserm team behind the discovery of a role for FXR in viral infections.

A first series of optimized molecules derived from these leads has been synthesized; these molecules, after screening on viral and ADMET (Absorption, Distribution, Metabolisme, Excretion and Toxicity) in vitro tests, must be tested ex vivo on CD4+ lymphocytes from the circulating peripheral reservoir of HIV+ patients in order to select the best molecules with LRA activity. This step is essential before considering the clinical development of an LRA.


Eligibility criteria: Inclusion Criteria:

* Criteria relating to the population studied: patients aged 18 to 65 years old, men or women, regardless of ethnic origin.
* Nosological criteria: HIV-1 infection, documented by a complete western blot and/or a detectable viral load at the time of diagnosis, regardless of the viral subtype.
* Pathology severity and progression criteria: patients with a CD4+ count greater than 500 elements/mm3 at the last follow-up visit prior to inclusion in the study. Undetectable viral load for at least six months on stable treatment.
* Criteria relating to treatments/strategies/procedures: Current cART treatment mandatory, regardless of the combination of anti-retrovirals, effective with undetectable viral load. The number of processing lines is not limited.
* Criteria relating to regulation: Absence of opposition

Exclusion Criteria:

* Criteria relating to the population studied: pregnant or breastfeeding women
* Criteria relating to contraindications to the protocol explorations:

Acute or chronic anaemias Acute infections, fever Coagulation disorders, patients taking anticoagulants

- Criteria relating to regulation: Subjects placed under judicial safeguard, guardianship or curatorship Subjects participating in another research with an ongoing exclusion period.

Primary outcomes:
measure: Measurement of the reactivation level and the EC50 of the optimized molecules.
timeFrame: At inclusion.
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Service des maladies infectieuses et tropicales Hôpital de la Croix Rousse
Study officials:
affiliation: Service des maladies infectieuses et tropicales, Hôpital de la Croix Rousse, Hospices Civils de Lyon
name: Tristan FERRY, MD-PhD
role: PRINCIPAL_INVESTIGATOR
References: